Cart
sales@molnova.com
Bromodeoxyuridine (BrdU)
CAS No. 59-14-3
Bromodeoxyuridine (BrdU)( BrdU | Bromodeoxyuridine | Broxuridine | NSC 38297 )
Catalog No. M15191 CAS No. 59-14-3
Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 27 | In Stock |
|
| 100MG | 38 | In Stock |
|
| 200MG | 42 | In Stock |
|
| 500MG | 52 | In Stock |
|
| 1G | 80 | In Stock |
|
Biological Information
-
Product NameBromodeoxyuridine (BrdU)
-
NoteResearch use only, not for human use.
-
Brief DescriptionBromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.
-
DescriptionBromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.
-
In Vitro——
-
In Vivo——
-
SynonymsBrdU | Bromodeoxyuridine | Broxuridine | NSC 38297
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number59-14-3
-
Formula Weight307.1
-
Molecular FormulaC9H11BrN2O5
-
Purity>98% (HPLC)
-
SolubilityEthanol: 3 mg/mL warmed (9.76 mM); DMSO: 61 mg/mL (198.63 mM); Water: <1 mg/mL
-
SMILESOC[C@@H]1[C@H](C[C@H](N2C(NC(C(Br)=C2)=O)=O)O1)O
-
Chemical Name5-Bromo-2'-deoxyuridine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Levkoff LH, et al. Neoplasia. 2008, 10(8), 804-816.
molnova catalog
related products
-
Neuropeptide AF (hNP...
Neuropeptide AF (hNPAF), Human
-
Sativanone
Sativanone has anti-inflammatory, anti-aging,anti Hyal-1 and antioxidant properties as well as antibacterial activity against Ralstonia solanacearum. Sativaone inhibits yeast alpha-glucosidase.
-
Mogroside III-A2
Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.
